Literature DB >> 22627004

Mitochondrial inhibitor models of Huntington's disease and Parkinson's disease induce zinc accumulation and are attenuated by inhibition of zinc neurotoxicity in vitro or in vivo.

Christian T Sheline1, Julia Zhu, Wendy Zhang, Chunxiao Shi, Ai-Li Cai.   

Abstract

BACKGROUND: Inhibition of mitochondrial function occurs in many neurodegenerative diseases, and inhibitors of mitochondrial complexes I and II are used to model them. The complex II inhibitor, 3-nitroproprionic acid (3-NPA), kills the striatal neurons susceptible in Huntington's disease. The complex I inhibitor N-methyl-4-phenylpyridium (MPP(+)) and 6-hydroxydopamine (6-OHDA) are used to model Parkinson's disease. Zinc (Zn(2+)) accumulates after 3-NPA, 6-OHDA and MPP(+) in situ or in vivo.
OBJECTIVE: We will investigate the role of Zn(2+) neurotoxicity in 3-NPA, 6-OHDA and MPP(+).
METHODS: Murine striatal/midbrain tyrosine hydroxylase positive, or near-pure cortical neuronal cultures, or animals were exposed to 3-NPA or MPP(+) and 6-OHDA with or without neuroprotective compounds. Intracellular zinc ([Zn(2+)](i)), nicotinamide adenine dinucleotide (NAD(+)), NADH, glycolytic intermediates and neurotoxicity were measured.
RESULTS: We showed that compounds or genetics which restore NAD(+) and attenuate Zn(2+) neurotoxicity (pyruvate, nicotinamide, NAD(+), increased NAD(+) synthesis, sirtuin inhibition or Zn(2+) chelation) attenuated the neuronal death induced by these toxins. The increase in [Zn(2+)](i) preceded a reduction in the NAD(+)/NADH ratio that caused a reversible glycolytic inhibition. Pyruvate, nicotinamide and NAD(+) reversed the reductions in the NAD(+)/NADH ratio, glycolysis and neuronal death after challenge with 3-NPA, 6-OHDA or MPP(+), as was previously shown for exogenous Zn(2+). To test efficacy in vivo, we injected 3-NPA into the striatum of rats and systemically into mice, with or without pyruvate. We observed early striatal Zn(2+) fluorescence, and pyruvate significantly attenuated the 3-NPA-induced lesion and restored behavioral scores.
CONCLUSIONS: Together, these studies suggest that Zn(2+) accumulation caused by MPP(+) and 3-NPA is a novel preventable mechanism of the resultant neurotoxicity.
Copyright © 2012 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22627004     DOI: 10.1159/000336558

Source DB:  PubMed          Journal:  Neurodegener Dis        ISSN: 1660-2854            Impact factor:   2.977


  15 in total

Review 1.  Neurotoxicity Linked to Dysfunctional Metal Ion Homeostasis and Xenobiotic Metal Exposure: Redox Signaling and Oxidative Stress.

Authors:  Carla Garza-Lombó; Yanahi Posadas; Liliana Quintanar; María E Gonsebatt; Rodrigo Franco
Journal:  Antioxid Redox Signal       Date:  2018-03-28       Impact factor: 8.401

Review 2.  Mitochondrial metals as a potential therapeutic target in neurodegeneration.

Authors:  A Grubman; A R White; J R Liddell
Journal:  Br J Pharmacol       Date:  2014-04       Impact factor: 8.739

3.  NAD(+) maintenance attenuates light induced photoreceptor degeneration.

Authors:  Shi Bai; Christian T Sheline
Journal:  Exp Eye Res       Date:  2012-12-26       Impact factor: 3.467

Review 4.  Coherent and Contradictory Facts, Feats and Fictions Associated with Metal Accumulation in Parkinson's Disease: Epicenter or Outcome, Yet a Demigod Question.

Authors:  Mohd Sami Ur Rasheed; Sonam Tripathi; Saumya Mishra; Mahendra Pratap Singh
Journal:  Mol Neurobiol       Date:  2016-08-01       Impact factor: 5.590

5.  Pyruvate Prevents Dopaminergic Neurodegeneration and Motor Deficits in the 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine Model of Parkinson's Disease.

Authors:  Yun-Mi Kim; Su Yeon Choi; Onyou Hwang; Joo-Yong Lee
Journal:  Mol Neurobiol       Date:  2022-09-03       Impact factor: 5.682

6.  Perturbation of transcription factor Nur77 expression mediated by myocyte enhancer factor 2D (MEF2D) regulates dopaminergic neuron loss in response to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).

Authors:  Matthew P Mount; Yi Zhang; Mandana Amini; Steve Callaghan; Jerzy Kulczycki; Zixu Mao; Ruth S Slack; Hymie Anisman; David S Park
Journal:  J Biol Chem       Date:  2013-03-27       Impact factor: 5.157

Review 7.  Neurodegeneration in Parkinson's disease: interactions of oxidative stress, tryptophan catabolites and depression with mitochondria and sirtuins.

Authors:  George Anderson; Michael Maes
Journal:  Mol Neurobiol       Date:  2013-10-02       Impact factor: 5.590

Review 8.  Synaptic Zinc: An Emerging Player in Parkinson's Disease.

Authors:  Joanna Sikora; Abdel-Mouttalib Ouagazzal
Journal:  Int J Mol Sci       Date:  2021-04-29       Impact factor: 5.923

Review 9.  Mechanisms of Metal-Induced Mitochondrial Dysfunction in Neurological Disorders.

Authors:  Hong Cheng; Bobo Yang; Tao Ke; Shaojun Li; Xiaobo Yang; Michael Aschner; Pan Chen
Journal:  Toxics       Date:  2021-06-17

10.  Transition metals activate TFEB in overexpressing cells.

Authors:  Karina A Peña; Kirill Kiselyov
Journal:  Biochem J       Date:  2015-06-11       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.